A Dutch study reveals that a crucial test to determine the necessity of chemotherapy for breast cancer patients is being underutilized. The test identifies patients who are unlikely to benefit from chemotherapy, potentially sparing them from debilitating side effects. Researchers found doctors are infrequently employing this genomic test, leading to some women undergoing chemotherapy unnecessarily. This underuse raises concerns about overtreatment and its impact on patients’ quality of life. The study highlights a gap between available medical advancements and their consistent implementation in clinical practice. Experts are now calling for wider adoption of the test to ensure patients receive the most appropriate and personalized treatment plans. Further investigation is needed to understand the reasons behind the limited uptake of this valuable diagnostic tool.